All News

Best of

U.S. News & World Report’s 2022–23 Rheumatology Rankings

Jack Cush, MD

The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.

Read Article
figure-1691868_640.jpg

TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted?

Jack Cush, MD

Management of arthralgias before a certified rheumatoid arthritis (RA) diagnosis is challenging - should one use DMARD therapy before clinically evident synovitis in a preemptive effort to avoid or forestall the diagnosis or damage of RA?

Read Article
pills,combo,push,blister

Continue the Methotrexate, Leave the Cannoli

Jack Cush, MD

Placebo responses are to be expected in rheumatoid arthritis (RA) clinical trials, but are such placebo responses affected by continuing background DMARDs like methotrexate (MTX) even though there was an inadequate response (IR) to MTX? 

Read Article
RF.jpg

Abatacept Most Effective Early and in Seropositive RA

Jack Cush, MD

An open-label, 2 year study evaluated the efficacy and safey (drug retention) of subcutaneous (SC) abatacept (ABA) in active rheumatoid arthritis (RA) and showed superior responses when ABA was given to biologic-naive and seropositive RA patients. 

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
infusion.biologic.jpg

ICYMI: Drug Survival Differences in RA, PsA, SpA and PsO

Jack Cush, MD

Drug survival may be the best measure of efficacy and safety. A study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.

Read Article
RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jack Cush, MD

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

Read Article
TNFinhib.jpg

Novel Anti-TNF Shines in Rheumatoid Arthritis Trial

MedPage Today

A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.

Read Article
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq

Links:

Dr. John Cush RheumNow ( View Tweet)
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4 Figures https://t.co/yIECjLiEwl

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of hospitalized infection (SIE) goes up with #RA disease activity. Study of 3,254 RA Pts with 529 SIE - SIE rates lowest with remission (3.8/100PY), vs low dz activity (6.6/100PY; OR 1.60) vs moderate activity (8.8/100PY; OR 183) https://t.co/EWbX7N7fiG https://t.co/Y8bRn2XATF

Links:

Dr. John Cush RheumNow ( View Tweet)
Sometimes the journey impacts as much as the destination. TREAT-EARLIER now @TheLancet: pre-RA (CSA+MRI) DBRCT: po MTX for 1y (+im mpred120x1) vs placebo eventual RA same but persistent benefit at 2y (1y post-MTX cessation): function, Sx, presenteeism, MRI a short thread🧵1/7 https://t.co/64b7us6hvS

Links:

David Liew drdavidliew ( View Tweet)

Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

Dr. John Cush RheumNow ( View Tweet)
#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network cc: @Yuz6Yusof : https://t.co/mn48vXtGad
Dr. John Cush RheumNow ( View Tweet)
Novel Anti-TNF Shines in Rheumatoid Arthritis Trial A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said. https://t.co/fTmWeIrVD5 https://t.co/LPk2Ok2gac

Links:

Dr. John Cush RheumNow ( View Tweet)
Placebo Works Best in Combination Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background MTX. https://t.co/JmNGRQWv6L https://t.co/77LdcTwCvl

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Post Hoc Analysis of the ORAL Surveillance Study https://t.co/PVzfYlzdQa https://t.co/0RpA3CfTEE

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of new onset #RA & undiff arthritis pts starting Rx 2005-2010; mean F/U 104 mos, 11% died. Steroids (<7.5/d) given to 44% initially, ultimately 57% w/ 20% recv >7.5/d. Steroids did not increase mortality (HR 1.35 ; 0.74, 2.47) or hospitalization https://t.co/KNpobs1UwH https://t.co/sjddMBKOeE

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×